Refractory thrombocytopenia (Q39438): Difference between revisions

From determinar.ia.br - Determine suas informações
Created a new Item
 
Changed an Item
 
(7 intermediate revisions by the same user not shown)
description / pt-brdescription / pt-br
 
Síndrome mielodisplásica caracterizada pela presença de pelo menos 10% de megacariócitos displásicos, encontrados dentre pelo menos 30 megacariócitos examinados na medula óssea.
description / endescription / en
 
A myelodysplastic syndrome characterised by the presence of at least 10% dysplastic megakaryocytes, found within at least 30 megakaryocytes examined in the bone marrow.
Property / Canonical URI
 
Property / Canonical URI: https://id.who.int/icd/entity/1018951801 / rank
 
Normal rank
Property / CURIE
 
CID11:2A32
Property / CURIE: CID11:2A32 / rank
 
Normal rank
Property / Canary Token
 
dki-india-2A32
Property / Canary Token: dki-india-2A32 / rank
 
Normal rank
Property / Verification Status
 
Concluído
Property / Verification Status: Concluído / rank
 
Normal rank
Property / Knowledge Architect
 
Property / Knowledge Architect: https://pauloleads.com.br/cases-publicos/ / rank
 
Normal rank
Property / Collection date
 
13 August 2026
Timestamp+2026-08-13T00:00:00Z
Timezone+00:00
CalendarGregorian
Precision1 day
Before0
After0
Property / Collection date: 13 August 2026 / rank
 
Normal rank
Property / Linked ICD 10
 
Property / Linked ICD 10: D46.9 / rank
 
Normal rank

Latest revision as of 04:51, 13 August 2026

A myelodysplastic syndrome characterised by the presence of at least 10% dysplastic megakaryocytes, found within at least 30 megakaryocytes examined in the bone marrow.
Language Label Description Also known as
default for all languages
2A32
    English
    Refractory thrombocytopenia
    A myelodysplastic syndrome characterised by the presence of at least 10% dysplastic megakaryocytes, found within at least 30 megakaryocytes examined in the bone marrow.

      Statements

      CID11:2A32
      0 references
      dki-india-2A32
      0 references
      Concluído
      0 references
      13 August 2026
      0 references
      0 references